

Monday 10 March 2008

Lifeline Scientific, Inc
("Lifeline" or "the Company")

**Lifeline division wins contracts to supply two leading transplant centres
with the LifePort® Kidney Transporter**

Lifeline Scientific, the medical technology company, announces that its Organ Recovery Systems division has signed contracts for its LifePort® Kidney Transporter with two of the world's largest kidney transplant centres, the Alabama Organ Center and the University Hospital of Wisconsin. Each has elected to use LifePort® to transport and preserve deceased donor kidneys offered for transplantation in their centres, which are reported to number, on average, 500 annually.

These contracts involve the sale of 14 LifePort Kidney Transporters as well as a significant volume of consumables each year. The contracts also cover ongoing warranty and maintenance services.

David Kravitz, Chief Executive of Lifeline Scientific, said:

"Securing contracts from two of the world's leading transplant centres is a significant accomplishment for our Organ Recovery Systems division, especially as it comes so soon after the completion of our IPO in January. Furthermore, adoption of our LifePort Kidney Transporter as standard practice in such prominent kidney transplant centres is a strong vote of confidence for our product. While January and February trading results have met management expectations, these contracts support our well paced momentum to meet our targets for 2008."

"With a continuing global shortage of organs for transplantation, it is important to find ways of increasing not only the number of kidneys available but also the quality of those organs which improves post transplant outcomes for patients."

Enquiries

Lifeline Scientific, Inc.	
David Kravitz, CEO ☐	
Seymour Pierce (Nomad)	+44 (0)20 7107 8000
Mark Percy / Huaizheng Peng / Sarah Jacobs ☐	
Financial Dynamics	+44 (0)20 7831 3113
Ben Brewerton / John Dineen ☐	

Notes to Editors

The LifePort Kidney Transporter preservation system is the Group's lead product. It is designed with the challenges of organ recovery and transport in mind, and provides a sealed, sterile, protected environment where a chemical solution is gently pumped through the donated kidney at cold temperatures to minimise tissue damage while the organ is outside the body.

Since receiving FDA clearance and CE Marking in 2004, over 250 LifePorts have been introduced in leading transplant programs throughout Europe and North America, preserving more than 10,000 kidneys for clinical transplantation.

Retrospective clinical outcomes studies have shown that machine preservation improves the quality of a kidney from a cadaveric donor prior to transplantation in comparison to organs statically stored in a traditional cool box. This data demonstrates that machine perfused kidneys are more likely to function immediately after transplantation and to remain healthier for longer.